Leadership Shakeup in MedTech: Boston Scientific, Medtronic, and Zeiss Announce Key Executive Changes

　　【Pharmaceutical Network Industry DynamicsSince December, there have been frequent changes in senior executives in the global medical device industry, involving several leading companies such as Boston Scientific, Zeiss Group, and Medtronic.
 

Recently, it was announced that Boston Scientific Corporation will see a high-level personnel change in its Cardiac Rhythm Management & Diagnostics (CRMDx) business by 2026. Scott Olson, Senior Vice President and President of the business unit, has announced plans to retire by the end of 2025.
 

It is reported that after Olson retires, Angelo De Rosa will take over in early 2026. In recent years, Angelo De Rosa has been responsible for and led the company's Watchman left atrial appendage closure business with remarkable achievements. After taking office, he will not only lead the CRMDx business but also join the Boston Scientific Executive Committee.
 

On December 8, Carl Zeiss Group announced that Maximilian Forster, CEO of its subsidiary Carl Zeiss Meditec, will step down at the end of the year due to violations of the company's internal code of conduct.
 

To address this unexpected change, ZEISS swiftly activated an emergency plan. Starting from January 1, 2026, Andreas Peucher, the Group's Global CEO, will temporarily take over as the CEO of the medical technology company to ensure there is no management vacuum. The Supervisory Board has immediately begun a global search for a permanent successor, with the goal of maintaining strategic continuity.
 

On December 8, Medtronic announced a key personnel appointment. Ms. Ingrid Goldberg has officially joined the company as Vice President and Head of Investor Relations. This appointment aligns with the strategic adjustments of the company's diabetes business unit (which is being spun off into an independent MiniMed company).
 

According to reports, Ms. Goldberg has over 20 years of industry experience, covering fields such as finance, medical devices, and life sciences. Before joining Medtronic, she served as the Vice President of Finance and Investor Relations at Novocure, responsible for investor relations, communications, and business development. Additionally, she held various leadership positions at Abiomed (now part of Johnson & Johnson Medical Technologies).
 

Notably, the above-mentioned companies have seen several executive changes this year. For instance, earlier this year, Medtronic's former Senior Vice President, Global Financial Controller and Chief Accounting Officer, Jennifer M. Kirkjiu1, officially left on May 2, 2025, to become the CEO of privately-held Exubrion Therapeutics. Denise L. Blomquist, then serving as Vice President, immediately assumed the position.
 

Subsequently, Medtronic Executive Vice President and Cardiovascular Portfolio President Sean Salmon departed, and Senior Vice President and President of Cranial and Spinal Technologies (CST) Skip Kiil was appointed as his successor. Additionally, Vice President and General Manager of the Spine division, Michael Carter, will take over from Kiil as the Senior Vice President and President of CST.
 

Industry analysis believes that the frequent changes of senior executives in the medical device industry in 2025 represent new transformations and trends in strategic adjustments, market expansion, digital transformation, and addressing regulatory challenges. Such changes may cause fluctuations in strategy execution in the short term, but will accelerate industrial integration and technological upgrades in the long term.
 

　　Disclaimer: In no event shall the information or opinions expressed in this article constitute investment advice to any person.